Polatuzumab Vedotin provides a CD79b-targeting antibody-drug conjugate (ADC) for lymphoma and oncology research. Also known as Polivy, it combines a CD79b-directed monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule-disrupting payload and specifically supports studies of B-cell lymphoma, targeted cytotoxicity, and antibody-mediated drug delivery.
Key Features and Benefits
- CD79b-Targeting ADC: Combines a CD79b-directed monoclonal antibody with the cytotoxic MMAE payload for targeted lymphoma research.
- MMAE Payload: Contains monomethyl auristatin E, a potent microtubule inhibitor specifically studied in ADC development.
- CD79b Recognition: Supports investigation of CD79b expression, antibody binding, internalization, and B-cell targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable valine-citrulline linker specifically designed to facilitate intracellular MMAE release.
- Targeted Payload Delivery: Supports investigation of antibody-mediated MMAE delivery to CD79b-expressing lymphoma cells.
- Microtubule Disruption: MMAE inhibits microtubule polymerization, specifically supporting studies of mitotic arrest and ADC-mediated cytotoxicity.
- B-Cell Receptor Research: Supports investigation of CD79b as a component of the B-cell receptor complex and its role in antibody internalization.
- Established ADC Platform: Provides a clinically established ADC platform specifically for studying CD79b-directed targeting and auristatin payload activity.
Applications
- Diffuse Large B-Cell Lymphoma Research: Supports investigation of CD79b-targeted ADC mechanisms in diffuse large B-cell lymphoma (DLBCL) models.
- B-Cell Lymphoma Research: Useful for studying ADC-mediated cytotoxicity in CD79b-expressing B-cell lymphoma models.
- CD79b-Positive Cancer Research: Supports investigation of antibody targeting and cytotoxic responses in CD79b-positive malignant cells.
- Non-Hodgkin Lymphoma Research: Useful for evaluating CD79b-directed ADC strategies in relevant non-Hodgkin lymphoma models.
- ADC Research: Supports studies of antibody binding, cellular uptake, intracellular processing, and payload release.
- Targeted Cancer Research: Enables investigation of antibody-mediated delivery of MMAE to CD79b-expressing cancer cells.
- Cell-Based Lymphoma Assays: Useful for evaluating CD79b-dependent binding, internalization, cytotoxicity, and apoptosis.
- Mechanism-of-Action Studies: Supports investigation of CD79b targeting and MMAE-mediated microtubule disruption.
- Comparative ADC Research: Useful for comparing B-cell-targeting antibodies, cleavable linker systems, and auristatin payloads.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve antibody and conjugate stability.
Polatuzumab Vedotin combines CD79b-directed antibody targeting with the microtubule-disrupting MMAE payload and specifically supports diffuse large B-cell lymphoma, CD79b-positive lymphoma, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
